Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-2752 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
mRNA-2752 + pembrolizumab is a combination therapy consisting of intratumoral injections of pembrolizumab (an immune checkpoint inhibitor) and mRNA-2752 (a lipid nanoparticle encoding three immunostimulatory proteins: OX40L, IL-23, and IL-36γ). This combination is designed to enhance anti-tumor immune responses by simultaneously blocking immune checkpoints and stimulating pro-inflammatory pathways within the tumor microenvironment. The therapy has shown promising results in high-risk ductal carcinoma in situ (DCIS), particularly in HER2-positive or hormone receptor-negative disease, with evidence of rapid tumor regression and immune infiltration.
- Brand names
- Keytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD28 (Cluster of Differentiation 28)IL23R (Interleukin-23 Receptor)IL1RL2 (Interleukin 36 Receptor)
Beyond the preview
Go deeper on mRNA-2752 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-2752 + pembrolizumab.